ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GC4006A

A development code.

Its studies are mostly in COVID-19, led by GC Biopharma.

Furthest: phase 2, since Oct 21, 20262 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GC Biopharma22 open or runningphase 2since Oct 21, 2026Jul 15, 2026May 2027phase 1 · NCT07728396

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2026First study: phase 1 study in COVID-19First studyNCT07728396 · 72 enrolled · South Korea
  2. Oct 21, 2026Phase 2 study in Covid-19 PreventionPhase 2 reachedNCT07936188 · 210 planned · South Korea

Ahead

  1. May 2027Primary completion: phase 1 study in COVID-19NCT07728396
  2. Oct 2027Primary completion: phase 2 study in Covid-19 PreventionNCT07936188

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07936188Covid-19 Prevention · South Korea2By invitationOct 2027210
NCT07728396COVID-19 · South Korea1Active, not recruitingMay 202772

How it is read

Names in the registry

  • “GC4006A”, 3 entries

Codes read as this program: GC4006A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.